Document Classification

Section Type: RESULTS

Text: For placebo, golimumab 50 mg and golimumab 100 mg, respective adverse event incidences/100 pt-yrs (95 % CIs) up to wk 160 were : 0. 28 (0. 01 to 1. 56), 0. 30 (0. 12 to 0. 62), 0. 41 (0. 23 to 0. 69) for death ; 5. 31 (3. 20 to 8. 30), 3. 03 (2. 36 to 3. 82), 5. 09 (4. 36 to 5. 90) for serious infection ; 0. 00 (0. 00 to 0. 84), 0. 17 (0. 05 to 0. 44), 0. 35 (0. 18 to 0. 62) for tuberculosis ; 0. 00 (0. 00 to 0. 84), 0. 13 (0. 03 to 0. 38), 0. 24 (0. 10 to 0. 46) for opportunistic infection ; 0. 00 (0. 00 to 0. 84), 0. 00 (0. 00 to 0. 13), 0. 12 (0. 03 to 0. 30) for demyelination ; and 0. 00 (0. 00 to 0. 84), 0. 04 (0. 00 to 0. 24), 0. 18 (0. 06 to 0. 38) for lymphoma.